Cynthia Owusu1,2, Seunghee Margevicius2,3, Mark Schluchter2,3, Siran M Koroukian2,3, Kathryn H Schmitz4, Nathan A Berger1,2. 1. Division of Hematology/Oncology, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio. 2. Case Comprehensive Cancer Center, Cleveland, Ohio. 3. Department of Epidemiology and Biostatistics, Case Western Reserve School of Medicine, Cleveland, Ohio. 4. Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: The purpose of this study was to determine the ability of the Vulnerable Elders Survey (VES-13) to predict the composite outcome of functional decline and death within 12 months of breast cancer treatment among women 65 years old or older with newly diagnosed stage I to III breast cancer. METHODS: Two hundred and six participants were recruited from ambulatory oncology clinics at an academic center between April 2008 and April 2013. Participants competed the VES-13 at baseline just before neoadjuvant/adjuvant treatment. The primary outcome, functional decline/death, was defined as either a decrease of at least 1 point on the Activities of Daily Living scale and/or the Instrumental Activities of Daily Living scale or death between baseline and 12 months (yes or no). RESULTS: One hundred and eighty four participants (89%) completed 12 months of follow-up. Twenty-two percent functionally declined (n = 34) or died (n = 7). Univariately, with increasing VES-13 scores, the estimated risk of functional decline/death rose from 23% for participants with a VES-13 score of 3 to 76% for participants with a VES-13 score of 10. In multivariate logistic regression analysis, VES-13 scores (adjusted odds ratio, 1.37; 95% confidence interval, 1.18-1.57) and having a high school education or less (adjusted odds ratio, 2.47; 95% confidence interval, 1.08-5.65) were independent predictors of functional decline/death (area under the receiver operator curve, 0.79). CONCLUSIONS: Among older women with newly diagnosed nonmetastatic breast cancer, approximately 1 in 5 functionally declined and/or died within 12 months of breast cancer treatment initiation. Women with high school education or less were disproportionately affected. The VES-13 is a useful instrument for the early identification of those at risk for functional decline and/or death. Cancer 2016;122:2579-86.
BACKGROUND: The purpose of this study was to determine the ability of the Vulnerable Elders Survey (VES-13) to predict the composite outcome of functional decline and death within 12 months of breast cancer treatment among women 65 years old or older with newly diagnosed stage I to III breast cancer. METHODS: Two hundred and six participants were recruited from ambulatory oncology clinics at an academic center between April 2008 and April 2013. Participants competed the VES-13 at baseline just before neoadjuvant/adjuvant treatment. The primary outcome, functional decline/death, was defined as either a decrease of at least 1 point on the Activities of Daily Living scale and/or the Instrumental Activities of Daily Living scale or death between baseline and 12 months (yes or no). RESULTS: One hundred and eighty four participants (89%) completed 12 months of follow-up. Twenty-two percent functionally declined (n = 34) or died (n = 7). Univariately, with increasing VES-13 scores, the estimated risk of functional decline/death rose from 23% for participants with a VES-13 score of 3 to 76% for participants with a VES-13 score of 10. In multivariate logistic regression analysis, VES-13 scores (adjusted odds ratio, 1.37; 95% confidence interval, 1.18-1.57) and having a high school education or less (adjusted odds ratio, 2.47; 95% confidence interval, 1.08-5.65) were independent predictors of functional decline/death (area under the receiver operator curve, 0.79). CONCLUSIONS: Among older women with newly diagnosed nonmetastatic breast cancer, approximately 1 in 5 functionally declined and/or died within 12 months of breast cancer treatment initiation. Women with high school education or less were disproportionately affected. The VES-13 is a useful instrument for the early identification of those at risk for functional decline and/or death. Cancer 2016;122:2579-86.
Authors: David B Reuben; Teresa E Seeman; Emmett Keeler; Risa P Hayes; Lee Bowman; Ase Sewall; Susan H Hirsch; Robert B Wallace; Jack M Guralnik Journal: Gerontologist Date: 2004-06
Authors: Cynthia Owusu; Mark Schluchter; Siran M Koroukian; Suzanne Mazhuvanchery; Nathan A Berger Journal: Cancer Date: 2013-09-23 Impact factor: 6.860
Authors: Jacqueline J Suijker; Bianca M Buurman; Marjon van Rijn; Marlies T van Dalen; Gerben ter Riet; Nan van Geloven; Rob J de Haan; Eric P Moll van Charante; Sophia E de Rooij Journal: J Clin Epidemiol Date: 2014-08-04 Impact factor: 6.437
Authors: Roland J Thorpe; Annemarie Koster; Hans Bosma; Tamara B Harris; Eleanor M Simonsick; Jacques Th M van Eijk; Gertrudis I J M Kempen; Anne B Newman; Suzanne Satterfield; Susan M Rubin; Stephen B Kritchevsky Journal: Ann Behav Med Date: 2012-02
Authors: Roland James Thorpe; Judith D Kasper; Sarah L Szanton; Kevin D Frick; Linda P Fried; Eleanor M Simonsick Journal: Soc Sci Med Date: 2007-12-27 Impact factor: 4.634
Authors: Lillian Min; William Yoon; Jeff Mariano; Neil S Wenger; Marc N Elliott; Caren Kamberg; Debra Saliba Journal: J Am Geriatr Soc Date: 2009-09-28 Impact factor: 5.562
Authors: Cynthia Owusu; Elizabeth Antognoli; Nora Nock; Paul Hergenroeder; Kristina Austin; Elizabeth Bennet; Nathan A Berger; Stephen Cerne; Katelyn Foraker; Kevin Heine; Ellen Heyman; Halle Moore; Jean Petkac; Mark Schluchter; Kathryn H Schmitz; Anastasia Whitson; Susan Flocke Journal: J Geriatr Oncol Date: 2018-01-03 Impact factor: 3.599
Authors: Supriya G Mohile; William Dale; Mark R Somerfield; Mara A Schonberg; Cynthia M Boyd; Peggy S Burhenn; Beverly Canin; Harvey Jay Cohen; Holly M Holmes; Judith O Hopkins; Michelle C Janelsins; Alok A Khorana; Heidi D Klepin; Stuart M Lichtman; Karen M Mustian; William P Tew; Arti Hurria Journal: J Clin Oncol Date: 2018-05-21 Impact factor: 44.544
Authors: Cynthia Owusu; Seunghee Margevicius; Nora L Nock; Kristina Austin; Elizabeth Bennet; Stephen Cerne; Paul Hergenroeder; Halle C F Moore; Jean Petkac; Mark Schluchter; Kathryn H Schmitz; Monica Webb Hooper; Leonard Wimbley; Nathan A Berger Journal: Cancer Date: 2022-03-15 Impact factor: 6.921
Authors: Melisa L Wong; Steven M Paul; Judy Mastick; Christine Ritchie; Michael A Steinman; Louise C Walter; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-23 Impact factor: 3.612
Authors: Cynthia Owusu; Nora L Nock; Paul Hergenroeder; Kristina Austin; Elizabeth Bennet; Stephen Cerne; Halle Moore; Jean Petkac; Mark Schluchter; Kathryn H Schmitz; Monica Webb Hooper; Lindsay Atkins; Oghenerukeme Asagba; Leonard Wimbley; Nathan A Berger Journal: Contemp Clin Trials Date: 2020-04-15 Impact factor: 2.226
Authors: Kah Poh Loh; Enrique Soto-Perez-de-Celis; Tina Hsu; Nienke A de Glas; Nicolò Matteo Luca Battisti; Capucine Baldini; Manuel Rodrigues; Stuart M Lichtman; Hans Wildiers Journal: J Oncol Pract Date: 2018-02 Impact factor: 3.714
Authors: C J Presley; Ling Han; Linda Leo-Summers; Arti Hurria; Cary P Gross; Amy J Davidoff; Heather G Allore; Thomas M Gill Journal: J Geriatr Oncol Date: 2018-06-22 Impact factor: 3.599